ArticleRheumatology and therapy2026
Renal Flares and Health-Related Quality of Life Among Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from the LUNAR Phase 3 Clinical Trial.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00282347 (A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreserving kidney function and limiting renal flares are important treatment goals for patients with lupus nephritis (LN). The relationship between renal flares and health-related quality of life (HRQOL) was assessed in patients with LN receiving standard therapy in the LUNAR phase 3 clinical trial.
methodsA post hoc analysis was conducted on data collected from patients with biopsy-confirmed class III/IV ± V LN randomized to the control arm of the phase 3 LUNAR (NCT00282347) trial. Relationships between renal flare(s) (estimated glomerular filtration rate decrease > 20% and urine-to-creatinine ratio [UPCR] > 1 g/g; increase in UPCR > 1 if UPCR < 0.2 g/g or UPCR > 2 if UPCR ≥ 0.2 g/g; or receipt of rescue therapy compared with week 16 when steroid tapering occurred) and mean change in HRQOL score across eight 36-Item Short Form Health Survey (SF-36) domains and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) were assessed using multivariate analysis of covariance (ANCOVA) modeling.
resultsAmong 72 patients receiving standard therapy, renal flare occurred in 24 patients (33%) (flare rate 3.18 per 1000 person days). Domain-specific mean SF-36 HRQOL scores and FACIT-Fatigue scores improved over time among study participants receiving standard therapy. Multivariate analyses identified a significant impact of experiencing one or more renal flares on mean change in FACIT-Fatigue score as well as the following SF-36 domains: physical functioning, role physical, bodily pain, vitality, and social functioning.
conclusionsRenal flares in patients with LN significantly impact their HRQOL as measured by the SF-36 and the FACIT-Fatigue, highlighting the importance of preserving kidney function from the patient perspective among those with LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.